Evidence map›Paper›PMID 29493085›Full record

ArticleCell proliferation2018

Overcoming resistance to mitochondrial apoptosis by BZML-induced mitotic catastrophe is enhanced by inhibition of autophagy in A549/Taxol cells.

Zhaoshi Bai, Meiqi Gao, Xiaobo Xu, Huijuan Zhang, Jingwen Xu, Qi Guan, Qing Wang, Jianan Du, Zhengqiang Li, Daiying Zuo and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell proliferation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MiR-217 regulates autophagy through OPG/RANKL/RANK in giant cell tumors.Journal of orthopaedic surgery and research · 2023
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zhaoshi BaiDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Meiqi GaoDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Xiaobo XuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Huijuan ZhangDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Jingwen XuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Qi GuanKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Qing WangKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Jianan DuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Zhengqiang LiDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Daiying ZuoDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.
Weige ZhangKey Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China.
Yingliang WuDepartment of Pharmacology, Shenyang Pharmaceutical University, Shenyang, China.ORCID http://orcid.org/0000-0002-5155-7568
Shenyang Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOur previous in vitro study showed that 5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) is a novel colchicine binding site inhibitor with potent anti-cancer activity against apoptosis resistance in A549/Taxol cells through mitotic catastrophe (MC). However, the mechanisms underlying apoptosis resistance in A549/Taxol cells remain unknown. To clarify these mechanisms, in the present study, we investigated the molecular mechanisms of apoptosis and autophagy, which are closely associated with MC in BZML-treated A549 and A549/Taxol cells.

methodsXenograft NSCLC models induced by A549 and A549/Taxol cells were used to evaluate the efficacy of BZML in vivo. The activation of the mitochondrial apoptotic pathway was assessed using JC-1 staining, Annexin V-FITC/PI double-staining, a caspase-9 fluorescence metric assay kit and western blot. The different functional forms of autophagy were distinguished by determining the impact of autophagy inhibition on drug sensitivity.

resultsOur data showed that BZML also exhibited desirable anti-cancer activity against drug-resistant NSCLC in vivo. Moreover, BZML caused ROS generation and MMP loss followed by the release of cytochrome c from mitochondria to cytosol in both A549 and A549/Taxol cells. However, the ROS-mediated apoptotic pathway involving the mitochondria that is induced by BZML was only fully activated in A549 cells but not in A549/Taxol cells. Importantly, we found that autophagy acted as a non-protective type of autophagy during BZML-induced apoptosis in A549 cells, whereas it acted as a type of cytoprotective autophagy against BZML-induced MC in A549/Taxol cells.

conclusionsOur data suggest that the anti-apoptosis property of A549/Taxol cells originates from a defect in activation of the mitochondrial apoptotic pathway, and autophagy inhibitors can potentiate BZML-induced MC to overcome resistance to mitochondrial apoptosis.

Indexed as

A549 CellsAnimalsAntineoplastic Agents, PhytogenicApoptosisAutophagyCytochromes cDNA DamageDrug Resistance, NeoplasmGlutathioneHumansImidazolesMaleMembrane Potential, MitochondrialMiceMice, Inbred BALB CMice, Nude5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl)imidazoleAntineoplastic Agents, PhytogenicCytochromes cGlutathioneImidazolesPaclitaxelReactive Oxygen Speciesapoptosis resistancecytoprotective autophagymitochondrial apoptotic pathwaymitotic catastropheNSCLC

Identifiers

PMID29493085
PMCPMC6528918
OpenAlexW2792598279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.